Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Identification and characterization of an activating F229V substitution in the V2 vasopressin receptor in an infant with NSIAD.

Carpentier E, Greenbaum LA, Rochdi D, Abrol R, Goddard WA 3rd, Bichet DG, Bouvier M.

J Am Soc Nephrol. 2012 Oct;23(10):1635-40. Epub 2012 Sep 6.

2.

Mutation in the V2 vasopressin receptor gene, AVPR2, causes nephrogenic syndrome of inappropriate diuresis.

Erdélyi LS, Mann WA, Morris-Rosendahl DJ, Groß U, Nagel M, Várnai P, Balla A, Hunyady L.

Kidney Int. 2015 Nov;88(5):1070-8. doi: 10.1038/ki.2015.181. Epub 2015 Jul 1.

PMID:
26131744
3.

Functional characterization of vasopressin type 2 receptor substitutions (R137H/C/L) leading to nephrogenic diabetes insipidus and nephrogenic syndrome of inappropriate antidiuresis: implications for treatments.

Rochdi MD, Vargas GA, Carpentier E, Oligny-Longpré G, Chen S, Kovoor A, Gitelman SE, Rosenthal SM, von Zastrow M, Bouvier M.

Mol Pharmacol. 2010 May;77(5):836-45. doi: 10.1124/mol.109.061804. Epub 2010 Feb 16.

4.

Characterization of three vasopressin receptor 2 variants: an apparent polymorphism (V266A) and two loss-of-function mutations (R181C and M311V).

Armstrong SP, Seeber RM, Ayoub MA, Feldman BJ, Pfleger KD.

PLoS One. 2013 Jun 6;8(6):e65885. doi: 10.1371/journal.pone.0065885. Print 2013.

5.

Agonist-independent interactions between beta-arrestins and mutant vasopressin type II receptors associated with nephrogenic syndrome of inappropriate antidiuresis.

Kocan M, See HB, Sampaio NG, Eidne KA, Feldman BJ, Pfleger KD.

Mol Endocrinol. 2009 Apr;23(4):559-71. doi: 10.1210/me.2008-0321. Epub 2009 Jan 29.

6.

Nephrogenic syndrome of inappropriate antidiuresis: a novel disorder in water balance in pediatric patients.

Gitelman SE, Feldman BJ, Rosenthal SM.

Am J Med. 2006 Jul;119(7 Suppl 1):S54-8.

PMID:
16843086
7.

Nephrogenic Syndrome of Inappropriate Antidiuresis in a Female Neonate: Review of the Clinical Presentation in Females.

Brachet C, Vandergheynst F, Heinrichs C.

Horm Res Paediatr. 2015;84(1):65-7. doi: 10.1159/000381586. Epub 2015 Apr 25. Review.

PMID:
25925274
8.

Nephrogenic syndrome of inappropriate antidiuresis (NSIAD): a paradigm for activating mutations causing endocrine dysfunction.

Rosenthal SM, Feldman BJ, Vargas GA, Gitelman SE.

Pediatr Endocrinol Rev. 2006 Dec;4 Suppl 1:66-70. Review.

PMID:
17261972
9.

Familial nephrogenic syndrome of inappropriate antidiuresis: dissociation between aquaporin-2 and vasopressin excretion.

Ranchin B, Boury-Jamot M, Blanchard G, Dubourg L, Hadj-Aïssa A, Morin D, Durroux T, Cochat P, Bricca G, Verbavatz JM, Geelen G.

J Clin Endocrinol Metab. 2010 Sep;95(9):E37-43. doi: 10.1210/jc.2009-2524. Epub 2010 Jul 14.

PMID:
20631022
10.

Nephrogenic syndrome of inappropriate antidiuresis secondary to an activating mutation in the arginine vasopressin receptor AVPR2.

Powlson AS, Challis BG, Halsall DJ, Schoenmakers E, Gurnell M.

Clin Endocrinol (Oxf). 2016 Aug;85(2):306-12. doi: 10.1111/cen.13011. Epub 2016 Feb 4.

PMID:
26715131
11.

[Vasopressin V2 receptor-related pathologies: congenital nephrogenic diabetes insipidus and nephrogenic syndrome of inappropiate antidiuresis].

Morin D.

Nephrol Ther. 2014 Dec;10(7):538-46. doi: 10.1016/j.nephro.2014.09.002. Epub 2014 Oct 25. Review. French.

PMID:
25449762
12.

Nephrogenic syndrome of inappropriate antidiuresis.

Feldman BJ, Rosenthal SM, Vargas GA, Fenwick RG, Huang EA, Matsuda-Abedini M, Lustig RH, Mathias RS, Portale AA, Miller WL, Gitelman SE.

N Engl J Med. 2005 May 5;352(18):1884-90.

13.

Lack of responsiveness to 1-desamino-D arginin vasopressin (desmopressin) in male patients with nephrogenic syndrome of inappropriate antidiuresis: from bench to bedside.

Vandergheynst F, Pradier O, Beukinga I, Kornreich A, Vassart G, Decaux G.

Eur J Clin Invest. 2012 Mar;42(3):254-9. doi: 10.1111/j.1365-2362.2011.02576.x. Epub 2011 Aug 11.

PMID:
21834801
14.

A family with hyponatremia and the nephrogenic syndrome of inappropriate antidiuresis.

Bockenhauer D, Penney MD, Hampton D, van't Hoff W, Gullett A, Sailesh S, Bichet DG.

Am J Kidney Dis. 2012 Apr;59(4):566-8. doi: 10.1053/j.ajkd.2011.09.026. Epub 2011 Dec 9.

PMID:
22154540
15.

The constitutively active V2 receptor mutants conferring NSIAD are weakly sensitive to agonist and antagonist regulation.

Tenenbaum J, Ayoub MA, Perkovska S, Adra-Delenne AL, Mendre C, Ranchin B, Bricca G, Geelen G, Mouillac B, Durroux T, Morin D.

PLoS One. 2009 Dec 21;4(12):e8383. doi: 10.1371/journal.pone.0008383.

16.

Mutations of Vasopressin Receptor 2 Including Novel L312S Have Differential Effects on Trafficking.

Tiulpakov A, White CW, Abhayawardana RS, See HB, Chan AS, Seeber RM, Heng JI, Dedov I, Pavlos NJ, Pfleger KD.

Mol Endocrinol. 2016 Aug;30(8):889-904. doi: 10.1210/me.2016-1002. Epub 2016 Jun 29.

17.

Thirst perception and arginine vasopressin production in a kindred with an activating mutation of the type 2 vasopressin receptor: the pathophysiology of nephrogenic syndrome of inappropriate antidiuresis.

Gupta S, Cheetham TD, Lambert HJ, Roberts C, Bourn D, Coulthard MG, Ball SG.

Eur J Endocrinol. 2009 Sep;161(3):503-8. doi: 10.1530/EJE-09-0246. Epub 2009 Jun 19.

18.

V2 vasopressin receptor (V2R) mutations in partial nephrogenic diabetes insipidus highlight protean agonism of V2R antagonists.

Takahashi K, Makita N, Manaka K, Hisano M, Akioka Y, Miura K, Takubo N, Iida A, Ueda N, Hashimoto M, Fujita T, Igarashi T, Sekine T, Iiri T.

J Biol Chem. 2012 Jan 13;287(3):2099-106. doi: 10.1074/jbc.M111.268797. Epub 2011 Dec 5.

19.
20.

Expression, purification and NMR characterization of the cyclic recombinant form of the third intracellular loop of the vasopressin type 2 receptor.

Bellot G, Pascal R, Mendre C, Urbach S, Mouillac B, Déméné H.

Protein Expr Purif. 2011 Aug;78(2):131-8. doi: 10.1016/j.pep.2011.04.020. Epub 2011 May 14.

PMID:
21575724

Supplemental Content

Support Center